Optical & Eyesight & Hyperbarics Directory

Hyperbaric oxygen therapy for mitomycin C-induced scleral necrosis.

Bayer A, Mutiu FM, Sobaci G.

Department of Ophthalmology Gulhane Military Medical Academy and Medical School, Ankara, Turkey.

Intraoperative or postoperative use of mitomycin C is one of the treatment options to reduce the recurrence of pterygia. Scleral necrosis, a potentially blinding complication after mitomycin C use, has been among great concern in ophthalmic practice. A patient is presented in whom scleral necrosis developed 20 days after a pterygectomy with bare sclera technique was performed, followed by the application of 0.4 mg/mL of topical mitomycin C eye drops for 3 weeks. After conjunctival flap failures the patient was treated with hyperbaric oxygen therapy. The sclera revascularized and returned to near normal thickness after 24 sessions of hyperbaric oxygen therapy. This case demonstrates that it is an effective, novel treatment.

Reprinted with Permission

Legal Disclaimer

The content and information provided within this site is for informational and educational purposes only. Consult a doctor before pursuing any form of therapy, including Hyperbaric Oxygen Therapy. The information provided within this site is not to be considered Medical Advice. In Full Support of the F D A., Hyperbaric Oxygen Therapy is considered Investigational, Experimental, or Off Label. Please consult with your Treating Medical Physician.